Board of Directors

Karessa's Board of Directors has four members whereof one is vacant. The work of the Board of Directors is led by its chairman. The Chairman of the Board is paid an annual director's fee of SEK 250,000 and to the other members who are not employees of the Company are paid an annual director's fee of SEK 100,000 per member.

Ulf Lindberg

Chairman

Born: 1952

Past experience: Senior positions within sales, marketing and clinical research Lederle and Pharmacia. Founder Eductus/Competencia. CEO Pricer USA.

Other current engagements include: CEO Enhancer AB

Shareholding: 0

Option holding: 0

Elected to the board since: 2017

Independent in relation to the company and the company management: Yes

Independent in relation to the company's major shareholders: Yes

Scott Boyer

Board member

Born: 1962

Education: PhD, University of Colorado, Boulder – Toxicology. NIH Fogarty International Centre Postdoctoral Fellow – Karolinska Institute

Other current engagements: Director – Computational Toxicology, Karolinska Institute, CEO, Klaria Pharmaceuticals AB

Previous directorships: -

Shareholding: 10,000

Option holding: 0

Elected to the board since: 2014

Independent in relation to the company and the company management: Yes

Independent in relation to the company's major shareholders: Yes

Stefan Arver

Board member

Born: 1952

Education: MD, PhD (Karolinska Institute), Registered medical practitioner, specialist in endocrinology

Other current engagements: Director European Academy of Andrology accredited Educational Centre in Andrology. Fellow and chief physician. Patient Flow manager ANOVA (Andrology, Sexual ­Medicine and Trans medicine) Karolinska University Hospital, Solna. Research group leader in Andrology, Sexual Medicine and Trans Medicine, Institue for Medicin Huddinge Karolinska Institute. Scientific adviser, consultant in the area of men's gender-specific diseases. Board member Acrosomen AB and Sarko AB, deputy board member Alabio AB.

Shareholding: 10,415

Option holding: 0

Elected to the board since: 2014

Independent in relation to the company and the company management: Yes

Independent in relation to the company's major shareholders: Yes